Lilly has agreed to acquire Curevo Vaccine, a biotech firm developing a next-generation shingles vaccine called amezosvatein, designed to improve tolerability and increase vaccination rates. The deal could pay Curevo shareholders up to $1.5 billion, including upfront and milestone payments. Amezosvatein showed promising Phase 2 results by matching immune response while significantly reducing side effects compared to current vaccines. Lilly aims to advance the vaccine into Phase 3 trials to offer better protection against shingles and its associated long-term risks like stroke and dementia.
Eli Lilly has finalized its acquisition of Centessa Pharmaceuticals, a company developing orexin receptor 2 agonists for narcolepsy and other sleep-wake disorders. This acquisition strengthens Lilly's neuroscience portfolio, aiming to address severe ...
President Trump highlighted the creation of over 2,600 manufacturing jobs in Pennsylvania during a visit to the Mack Trucks facility. He credited his administration's policies, including rolling back stringent fuel emissions regulations, for boosting...
The 16th annual PODD (Partnership Opportunities in Drug Delivery) conference will take place on October 29-30, 2026, in Boston, gathering over 1,000 industry leaders to discuss advancements in drug delivery systems. The event features over 150 sessio...
Illumina appointed Dr. Daniel M. Skovronsky, Chief Scientific and Product Officer at Eli Lilly, to its Board of Directors. His expertise in drug discovery and clinical development aligns with Illumina's focus on genomics and multiomics innovation. Th...
New long-term data from the ADjoin trial shows that lebrikizumab, an injectable treatment for moderate to severe atopic dermatitis, maintains skin clearance and reduces itching for up to 2 years even with monthly dosing instead of biweekly. About 76%...
